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Gene expression in hypothalamus, liver, and adipose tissues and food
intake response to melanocortin-4 receptor agonist in pigs expressing
melanocortin-4 receptor mutations
Abstract
Transcriptional profiling was used to identify genes and pathways that responded to intracerebroventricular
injection of melanocortin-4 receptor (MC4R) agonist [Nle4, D-Phe7]-α-melanocyte stimulating hormone
(NDP-MSH) in pigs homozygous for the missense mutation in the MC4R, D298 allele (n = 12), N298 allele
(n = 12), or heterozygous (n = 12). Food intake (FI) was measured at 12 and 24 h after treatment. All pigs
were killed at 24 h after treatment, and hypothalamus, liver, and back-fat tissue was collected. NDP-MSH
suppressed (P < 0.004) FI at 12 and 24 h in all animals after treatment. In response to NDP-MSH, 278 genes
in hypothalamus (q ≤ 0.07, P ≤ 0.001), 249 genes in liver (q ≤ 0.07, P ≤ 0.001), and 5,066 genes in fat (q ≤
0.07, P ≤ 0.015) were differentially expressed. Pathway analysis of NDP-MSH-induced differentially expressed
genes indicated that genes involved in cell communication, nucleotide metabolism, and signal transduction
were prominently downregulated in the hypothalamus. In both liver and adipose tissue, energy-intensive
biosynthetic and catabolic processes were downregulated in response to NDP-MSH. This included genes
encoding for biosynthetic pathways such as steroid and lipid biosynthesis, fatty acid synthesis, and amino acid
synthesis. Genes involved in direct energy-generating processes, such as oxidative phosphorylation, electron
transport, and ATP synthesis, were upregulated, whereas TCA-associated genes were prominently
downregulated in NDP-MSH-treated pigs. Our data also indicate a metabolic switch toward energy
conservation since genes involved in energy-intensive biosynthetic and catabolic processes were
downregulated in NDP-MSH-treated pigs.
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Transcriptional profiling was used to identify genes and pathways that
responded to intracerebroventricular injection of melanocortin-4 re-
ceptor (MC4R) agonist [Nle4, D-Phe7]--melanocyte stimulating hor-
mone (NDP-MSH) in pigs homozygous for the missense mutation in
the MC4R, D298 allele (n  12), N298 allele (n  12), or heterozy-
gous (n  12). Food intake (FI) was measured at 12 and 24 h after
treatment. All pigs were killed at 24 h after treatment, and hypothal-
amus, liver, and back-fat tissue was collected. NDP-MSH suppressed
(P  0.004) FI at 12 and 24 h in all animals after treatment. In
response to NDP-MSH, 278 genes in hypothalamus (q  0.07, P 
0.001), 249 genes in liver (q  0.07, P  0.001), and 5,066 genes in
fat (q  0.07, P  0.015) were differentially expressed. Pathway
analysis of NDP-MSH-induced differentially expressed genes indi-
cated that genes involved in cell communication, nucleotide metabo-
lism, and signal transduction were prominently downregulated in the
hypothalamus. In both liver and adipose tissue, energy-intensive
biosynthetic and catabolic processes were downregulated in response
to NDP-MSH. This included genes encoding for biosynthetic path-
ways such as steroid and lipid biosynthesis, fatty acid synthesis, and
amino acid synthesis. Genes involved in direct energy-generating
processes, such as oxidative phosphorylation, electron transport, and
ATP synthesis, were upregulated, whereas TCA-associated genes
were prominently downregulated in NDP-MSH-treated pigs. Our data
also indicate a metabolic switch toward energy conservation since
genes involved in energy-intensive biosynthetic and catabolic pro-
cesses were downregulated in NDP-MSH-treated pigs.
melanocyte-stimulating hormone; microarray; hypothalamus; MC4R
THE CURRENT KNOWLEDGE OF FACTORS regulating voluntary food
intake in humans and domestic animals is very limited. The
majority of this knowledge is based on studies in rodents (52,
70). Numerous reports have demonstrated that the hypotha-
lamic melanocortin system plays a major role in regulating
appetite and energy homeostasis (1, 8, 14). The regulation of
the melanocortin system is via the melanocortin receptor ago-
nist, alpha-melanocyte stimulating hormone (-MSH), which
is derived from proopiomelanocortin (POMC), and the antag-
onist, agouti-related protein (AgRP). Both AgRP and POMC
have been identified in the hypothalamus of the pig (19, 44),
and their action is mediated by the melanocortin-3 and 4-re-
ceptor (MC3R and MC4R; 22, 23). In mice, central adminis-
tration of AgRP or the MC4R antagonist SHU9119 robustly
increased feeding behavior, indicating that antagonism of the
MC4R is an important orexigenic signal (27, 73). In POMC
and MC4R knockout mice (9) and mice overexpressing AgRP
(29), the same obese phenotype is exhibited. A similar pheno-
type was observed in humans with mutations in MC4R (24).
Thus, a functional MC4R plays a pivotal role in the regulation
of energy homeostasis.
Rothschild and coworkers identified a missense mutation
(D298N) in the porcine MC4R (pMC4R) gene that changes a
highly conserved aspartic acid in TM7 in melanocortin recep-
tors to asparagine (42). Moreover, this missense mutation is
associated with increased food intake, growth, and fatness (42).
A structure and function relationship has been observed in
natural and experimentally induced MC4R mutations in hu-
mans (69, 51) and mice (53). Furthermore, highly conserved
residues in the MC4R protein structure may be critical for
ligand binding and signal transduction (59, 68). Recent find-
ings revealed that cell lines transfected with the porcine MC4R
D298N mutation had decreased cAMP production when stim-
ulated with the MC4R agonist compared with cells transfected
with the wild-type receptor (43). In direct contrast to this
report, Fan et al. (23), using the same experimental paradigm,
demonstrated that in cells transfected with MC4R, the D298N
mutation failed to alter MC4R signaling or cAMP content. We
have previously reported that central administration of a
MC3/4R agonist,[Nle4, D-Phe7] (NDP)-MSH, suppressed food
intake in pigs. In contrast treatment with a MC3/4R antagonist,
SHU9119, failed to stimulate intake, whereas AgRP ability to
increase feeding behavior was equivocal (6). Moreover, these
pigs were heterozygous for the MC4R mutation. Clearly,
further work is needed to understand the functional role of
MC4R on the genetic and metabolic pathways involved in
appetite and growth. Therefore, the purpose of the present
study was, first, to test the idea that food intake response to
intracerebroventricular (ICV) injection of the MC4R agonist,
NDP-MSH, is MC4R genotype dependent and, second, to
determine whether genes and pathways that respond to central
Address for reprint requests and other correspondence: C. R. Barb, USDA,
ARS, Richard B. Russell Agriculture Research Center, 950 College Station
Rd., Athens, GA, 30605 (e-mail: Richard.barb@ars.usda.gov).
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administration of NDP-MSH are affected in pigs with alternate
MC4R genotypes.
MATERIALS AND METHODS
Twelve crossbred prepuberal gilts and six male castrates, 64 2 kg
body weight, and 130–140 days of age were used. Pigs were screened
for MC4R genotype with a missense mutation in the MC4R (D298N;
42), which has been associated with increased food efficiency. Pigs
homozygous for MC4R, D298 allele (n  6), or N298 allele (n  6)
or heterozygous (n 6) were selected from the University of Georgia
swine herd (PIC composite). In a complete 2  3 factorial design,
within each genotype, two gilts and one male were assigned to each
of the hormonal treatments. All pigs were surgically implanted with
lateral ICV cannulas with the stereotaxic procedure of Estienne et al.
(20) and Barb et al. (5). Animals were individually penned in an
environmentally controlled building at a constant temperature of 22°C
and artificial 12:12-h light-dark photoperiod. Pigs were fed ad libitum
a corn-soybean meal ration (14% crude protein) supplemented with
vitamins and minerals, according to the National Research Council
(NRC) guidelines (57). One week after the last ICV surgery, feeders
were removed at 0700, ICV injections of 150 l 0.9% saline (n  9)
or 10 g of the MC3/4R agonist [Nle4, D-Phe7]--MSH (NDP-MSH;
Bachem, Torrance, CA; n  9) were administered at 0800, feeders
were placed in all pens, and food intake was monitored at 12 and 24
h after feed presentation. All pigs were killed 24 h postinjection, and
hypothalamus, liver, and 10th rib middle layer of subcutaneous
adipose tissue were collected as previously described (4, 33). mRNA
was isolated as described previously (30, 32) and was hybridized to
Affymetrix Gene Chip Porcine Genome Arrays containing 24,123
probe sets. A second replicate was conducted as described above with
an additional 12 prepuberal gilts and six castrate males averaging 77
 2 kg and 140 days of age; within each genotype, two gilts and one
male were assigned to each of the treatments. This resulted in the
following groups for the two replicates: saline (n  6/D298, n 
6/N298, n 6/D298N), 10 g NDP-MSH (n 6/D298, n 6/N298,
n  6/D298N). All procedures were approved by the Richard B.
Russell Agriculture Research Center Committee on Animal Care and
Use.
Isolation of Total RNA
Total RNA was isolated from hypothalamus, liver, and adipose
tissues for each pig (n  36 pigs) by extraction with QIAzol Lysis
Reagent (Qiagen, Valencia, CA) followed by isopropanol precipita-
tion of the aqueous phase. RNA was resuspended in water and
immediately purified on Qiagen’s RNEasy Mini Columns according
to the manufacturer’s procedure. Total RNA quality and quantity were
determined by microfluidic analysis on an Agilent 2100 Bioanalyzer
(Agilent Technologies, Foster City, CA). Each RNA extract was
divided into aliquots for use with Affymetrix Gene Chips, and for
quantitative real-time PCR (qPCR) on liver and adipose from each of
the 36 animals and hypothalamus from 32 of the 36 were used. Four
of the hypothalamus samples had been used up for the microarrays.
Theses included two heterozygous females (one control and one
treated) and two N298 animals (one female control and one male
treated).
Affymetrix Arrays
Affymetrix GeneChip Porcine Genome Arrays (Affymetrix, Santa
Clara, CA) were processed at Yerkes Microarray Core at Emory
University in Atlanta, GA. Standard labeling of target (one round
amplification), hybridization to GeneChip Porcine Genome Arrays
(hybridization, washing, staining, and scanning), and data extraction
and analysis were carried out on an Affymetrix GeneChip Instrument
System (GeneChip Scanner 3000, Fluidic Stations 450, Hybridization
Oven 640, and computer workstation loaded with GeneChip Operat-
ing Software) using the manufacturer’s reagents and protocols. Target
was prepared using Affymetrix’s One-Cycle Eukaryotic Target La-
beling Assay with 5 g total RNA as starting material. Briefly, the
RNA was reverse-transcribed into double-stranded complementary
deoxyribonucleic acid (cDNA), which was subsequently transcribed
into biotin-labeled complementary RNA with simultaneous amplifi-
cation. The resulting target was hybridized to GeneChip Porcine
Genome Arrays.
Gene Ontology Biological Process Enrichment and Pathway
Analysis
Annotation of human homologs of the Affymetrix porcine probe
sets (67) with gene names and Gene Ontology (GO) enrichment
analysis was performed by tools available at DAVID Bioinformatics
Resources (18). The transcriptome background for each tissue con-
sisted of all genes flagged as present, marginal, or unknown on at least
one of the GeneChip Porcine Genome Arrays for that tissue and that
were matched to a human homolog. Redundancies caused by multiple
probe sets that were annotated to the same gene were eliminated. This
resulted in a transcriptome of 10,866 genes for hypothalamus, 10,484
genes for liver, and 10,681 genes for adipose tissue. For GO enrich-
ment analysis, the lists of differentially expressed genes (q  0.07)
were divided into up and down expression by tissue, and redundant
genes were eliminated. Each list was analyzed for overrepresentation
(enrichment P  0.1) in all levels of GO Biological Processes using
DAVID’s Gene Functional Annotation tool with medium stringency
settings. GO enrichment cluster themes were denoted by the biolog-
ical process with the smallest P value for each cluster. For pathway
analysis, the top 50 most differentially expressed (up or down) genes
by fold change in adipose tissue and genes with log fold changes of
0.57 and  0.57 in hypothalamus and liver were analyzed for
overrepresentation in KEGG pathways (Kyoto Encyclopedia of Genes
and Genomes, release 49.0) (38–40). Pathway themes were deter-
mined by KEGG orthology identifiers in KEGG’s BRITE database.
qPCR
Custom Taqman Gene Expression Assays (forward primer, reverse
primer, and 6FAM dye: MGB-labeled probe) were designed by
Applied Biosystems (Foster City, CA) from sequences that were
based on GenBank or The Institute for Genomic Research (TIGR) Pig
Gene Index records and that were assessed for quality according to
Applied Biosystems guidelines (Table 1). A custom porcine 18S
rRNA assay was designed as an endogenous control. We transcribed
3 g total RNA was transcribed into cDNA in a volume of 20 l with
Superscript III First-Strand Synthesis System (Invitrogen, Carlsbad,
CA) utilizing random hexamers and following the manufacturer’s
protocol (25°C for 10 min, 50°C for 50 min). The cDNA was diluted
1:10 for use as template in the amplification reaction. The amplifica-
tion reaction consisted of 1 l diluted cDNA, 10 l iQ Supermix
(Bio-Rad Laboratories, Hercules, CA), 0.8 l 20 custom TaqMan
Gene Expression Assay, and water up to a total volume of 20 l. To
measure each assay’s probe reaction efficiency, a series of 20 l
reactions was performed similar to the above using as template 1 l
of a threefold to 2,187-fold range of serial dilutions of a pool of all
available cDNAs. PCR was performed in Bio-Rad’s CFX 96 Real-
Time PCR Detection System. Thermal cycling parameters were as
follows: an initial denaturation step (95°C for 10 min), followed by 40
cycles of denaturation and annealing/extension (95°C for 15 s, 60°C
for 1 min) in a 96-well optical plate.
Analysis of qPCR data
Ct (threshold cycle) values were determined using Bio-Rad’s CFX
Manager Software. Automatic background fluorescence and thresh-
olds were checked, and no adjustments were determined necessary.
Within-sample triplicate well reactions that did not fall within one
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Table 1. Primer pair, probe sequence, and GenBank accession number for each gene
Gene Symbol GenBank Accession Number
1. Forward Primer Sequence (5= to 3=)
2. Reverse Primer Sequence (5= to 3=)
3. Reporter Sequence (5= to 3=) Design Strand
Amplicon
Length, bp
3-beta-Hydroxysteroid
dehydrogenase/delta-5-
delta-4 isomerase
3B-HSD NM_001004049 1. GCGCCGTACCCCTTGA reverse 65
2. AGAGCCCAGCCGTTAGC
3. TCAGCCAGCTTTTTGC
Acyl-CoA synthetase long-
chain family member 3
ACSL3 NM_001143698 1. TGAGTCAAGGCAAGAAAAATCAAACC reverse 100
2. AGCCAAACCATCCAAGCTGTTAA
3. ACAGGCTTTGCTTTAATG
ADP-ribosylation factor-like
protein 3
ARL3 NM_001031785 1. GTAATTGACAGCGCAGACAGAAAA forward 94
2. GCACTGGAACACAACTTAGCTTTT
3. ACGGGTCAGGAACTAG
Angiogenin ANG1 NM_001044573 1. ACCTTTATTCATGGCACGAGGAA forward 93
2. AGGAGACTTGCTTCTTCTGAAATTGT
3. AAGGCCATCTGTAATGAT
Angiopoietin-like 4 ANGPTL4 NM_001038644 1. ACTGCCAAGAGCTGTTTGAAGA reverse 106
2. CCATCTGAGGTCATCTTGCAGTTAA
3. CTTTGCCGCTCTCCC
Cytochrome c oxidase
subunit VIIc
COX7C NM_001097474 1. CAGGGAAGAATTTGCCATTTTCAGT reverse 84
2. CAGCAAATCCAGATCCAAAGTACAG
3. CCGCCACTTATTTTC
Epidermal growth factor
receptor
EGFR NM_214007 1. TGATCCAGGCTGTCTCAATGG forward 83
2. GCTGGGCACAGATGACTTTG
3. ACTGCCAGAAATTGAC
Fatty acid binding protein 3,
muscle and heart
(mammary-derived
growth inhibitor)
FABP3 NM_001099931 1. TTCGGGAACTAGTTGATGGGAAAC forward 72
2. CGTAAGTGCGAGTGCAAACTG
3. TCATCCTGACACTCACCC
Fatty acid synthase FASN NM_001099930 1. GCTTGTCCTGGGAAGAGTGTAAG forward 77
2. CACCGTGTCTTTGGAGTTGTG
3. CAGCGCTGCCCCC
Galactosylceramidase GALC CF793186 1. GGCTTCCTGCCATGACAGAATTA forward 63
2. GTTGACCGTGTGTCTGAGTGA
3. CCCACGACGAGGACAC
Interleukin 15 IL15 NM_214390 1. TTTAACTGAGGATGGCATTCATGTCTT reverse 77
2. GCCAGGTTGCTTCTGTTTTAGGA
3. CTGATACAGCCCAAAATG
Karyopherin alpha 4 KPNA4 AY010067 1. GCTCAGCCACCAGGAAGTT reverse 53
2. TGCCCACAGCTCGAAGTG
3. CTGCTGTCTGAACTTT
Leptin LEP NM_213840 1. GACGATTGTCACCAGGATCAGT forward 68
2. CGGTGACCCTCTGTTTGGA
3. CACATGCAGTCTGTCTCC
Lipoprotein lipase LPL NM_214286 1. TGGCATTGCAGGAAGTCTGA reverse 95
2. GGCTTGGAGCTTCTGCATACTC
3. ATCTAGGCCAGTAATTCT
Malate dehydrogenase 1,
NAD (soluble)
MDH1 NM_213874 1. GCTGCCTTGGACAAATATGCTAAGA reverse 71
2. CAGTTGGTATTGGCTGGGTTTC
3. CCACCACGATAACCTT
NAD(P)H dehydrogenase,
quinone 1
NQO1 BQ601005 1. AGATTCTGTCTTTTCTTTCTCCAAGCA forward 94
2. CACCCAACTCCTCAATGGTCTTA
3. CTCTTCTGCCATAAACCA
Neuropeptide Y NPY AF264083 1. TCGGCGTTGAGACATTACATCA forward 68
2. GTCTCGGGACTAGATCGTTTTCC
3. CACCAGGCAGAGATAC
Symplekin SYMPK CN158843 1. GGCCTGTTGCTCTGTATATTCTGT forward 79
2. ACTTTACAGTTCTTTTCCCAGATGCT
3. ATGCCATGCTATGTCTAACA
Solute carrier family 1
(neuronal/epithelial high-
affinity glutamate
transporter, system Xag),
member 1
SLC1A1 AY195622 1. TCTCCTGACAGCTCTCATGATCTC forward 64
2. AGCACAGCGGAAAGTGACA
3. CTCCAGTTCAGCAACACT
Uncoupling protein 3 UCP3 NM_214049 1. ACCATCGCCAGGGAGGAA reverse 63
2. CCTCGTGATGTTGGGCAGAATT
3. CCTTTCCACAGGCCCC
Phosphodiesterase 4D1 PDE4D EF109889 AAGTTCTGGAGTTCTTCTTCTTGAT3 N/A 119
Protein kinase, cGMP-
dependent, type I2
PRKG1 NM_001044574 TCATTCTGATTTCATAGTGAGATTA3 N/A 117
1Noncustom Taqman Gene Expression Assay ID Ss03377183_u1; target exon 9. 2Noncustom Taqman Gene Expression Assay ID Ss03388356_g1; target exon
1. 3Context sequence of noncustom Taqman Gene Expression Assay.
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cycle of each other were repeated, and the original reactions were
excluded from analysis. The Ct values of within-sample triplicate wells
were averaged. Relative differences in gene expression were calculated
by the Relative Expression Software Tool (REST) procedure (60). Sam-
ple, endogenous control, and probe reaction efficiency Cts were imported
into REST V2.0.7 2008 (Corbett Research, Sydney, Australia). Biolog-
ical replicates were not averaged before import. Statistical significance
was set at (P  0.05), and the reference gene was 18S rRNA. The ratio
compared the expression of treated to untreated. Ratios are reported as
1 divided by the ratio if downregulated to correct for nonlinear
appearance, with positive numbers indicating upregulation, negative
numbers indicating downregulation, and a ratio of 1 indicating no
differential expression.
Analysis of Affymetrix Data
Data preprocessing. The background adjustment was done in R
using the Affymetrix Bioconductor software, which is a widely used
program for the analysis and interpretation of data arising from
high-throughput experimentation in genomics and molecular biology.
Probe intensities were adjusted based upon a weighted average of the
backgrounds for each region. The weights are based on the distances
between the location of the probe and the centroids of 16 different
regions. Although perfect match (PM) and mismatch (MM) probe
level can be used in the statistical analysis, several studies (13) have
reported the limited contribution of MM data as well as the potential
for adding more noise; consequently, only PM data were used in this
study.
A scaling/linear method for normalizing the raw Affymetrix data
was used in the analysis. This method was implemented by selecting
a baseline array and then fitting a linear regression without intercept
term between each array and the chosen array. The resulting fitted
regression line is used as the normalizing relationship. We used the
Affymetrix package of the Bioconductor for preprocessing the raw
data; it has many methods for background adjustments as well as data
normalization of Affymetrix microarray data. The log base 2 trans-
formation was performed on the background-adjusted and normalized
PM intensities as suggested by previous studies (37).
Statistical analysis. In typical microarray experiments, several
systematic and random effects contribute to the observed variation in
the data. The use of mixed linear models for the analysis of microarray
data (74) provides a flexible tool for accommodating these effects.
In this study, the following mixed linear model was used to analyze
the probe level intensities for every gene separately: PMijklmo   
tri  genoj  arrayk  sexl  (tr*geno)ij  eijklmo, where PMijklmo
is the log2-transformed intensity for probe for gene m for sample o, trti
is the treatment effect (i  1,2); genoj is the effect of genotype (j 
1,2,3), arrayk is the random effect of array (k  1,2,36), sexl is the
effect of sex (l  1,2), (trt*geno)ij is the interaction effect between
treatment and genotype, and eijklmo is the residual term. It is important
to note that the number of probes per gene ranged from 11 to 20.
Furthermore, the following assumptions were made about the distri-
bution of the random effects in the model: eijk 	 N(0, 
e2) and Ak 	
N(0, 
a2), where 
e2 and 
a2 are the within and between array variances,
respectively. Proc mixed of Statistical Analysis System (SAS; 48) was
used for fitting the mixed linear model, and the restricted maximum-
likelihood method was used to estimate the variance components.
The contrast statement was used to estimate and test linear com-
binations of interest. Degrees of freedom for F-test were estimated
using the satterthwaite option in SAS proc mixed. Least-square
estimates of both treatments for each single gene were calculated
using the LSMEANS statement of SAS.
Multiple comparisons. Due to the large number of genes tested in
microarray studies a method to assess the number of false positives is
of great importance. In this study, the Hochberg-Benjamini method
(36) for false discovery rate calculation was used to account for the
multiple comparisons. The method can be summarized in the follow-
ing three steps:
1) For a given significance level, e, genes were ranked by their P
values from the most to the least significance.
2) A threshold value was calculated for each gene as: Thresholdi 
(Ri*e)/N, where Ri is the rank of gene i and N is the total number of
genes in the array.
3) Each P value was then compared with its respective threshold,
starting with the most significant P value, until a P value greater than
the threshold value is encountered.
Statistical Analysis of Feed Intake Data
To determine the effect of treatment and genotype on feed intake
across time, data were subjected to the general linear model split
plot-in-time ANOVA procedure of SAS (63). The statistical model
included treatment, pig, genotype, replicate, and time. Effects of
treatment were tested using animal within dose as the error term. Time
was tested using dose  time as the error term and dose  time was
tested by the residual. Differences between treatment means within a
time were determined by least-squares contrasts (63).
RESULTS
NDP-MSH suppressed (P  0.004) food intake at 12 and 24
h in all animals after treatment (Fig. 1). There was no replicate,
genotype, or treatment  genotype interaction detected (P 
0.8). Although NDP-MSH treatment suppressed food intake,
these animals consumed enough feed to meet maintenance
requirements according to NRC requirements for swine.
Microarray Data Validation
Expression of unique upregulated and several downregu-
lated genes in the microarray analysis of NDP-MSH treatment
and controls was verified by qPCR in fat, liver, and hypotha-
lamic tissue (Table 2). In fat, these included downregulated
lipid biosynthetic genes, i.e., fatty acid synthase (FASN) and
lipoprotein lipase (LPL). Upregulated genes included 3-
beta-hydroxysteroid dehydrogenase/delta-5-delta-4 isomerase
(HSD3B1), angiopoietin-like-4 (ANGPTL4) and uncoupling
protein 3 (UCP3). Other noteworthy genes not verified in-
Fig. 1. Cumulative food intake (mean  SE) for pigs homozygous for
melanocortin-4 receptor (MC4R), D298 allele (n  12), N298 allele (n  12),
or heterozygous (n  12). Six pigs from each genotype received intracerebro-
ventricular (ICV) injections of 150 l saline or 10 g of the MC3/4R agonist
[Nle4, D-Phe7] melanocyte-stimulating hormone (NDP-MSH). There was no
replicate or treatment  genotype interaction detected (P  0.8). Times at
which effects of treatment were different from saline-treated animals *(P 
0.004).
257MSH EFFECTS ON PATHWAYS IN HYPOTHALAMUS LIVER AND FAT
Physiol Genomics • VOL 41 • www.physiolgenomics.org
cluded interleukin 15 (IL-15), and angiogenin (ANG1). In
liver, downregulated genes included lipid biosynthetic and
energy metabolism genes, i.e., NAD(P)H dehydrogenase, qui-
none 1; malate dehydrogenase-1, Nad (MDH1); and cyto-
chrome C oxidase subunit 7c (COX7C). In the hypothalamus,
statistical significance of the fold changes of solute carrier
family 1 member 1, karyopherin-4, and neuropeptide Y
(NPY) was verified by qPCR (P  0.05). Overall, the results
obtained from microarray were confirmed for these sets of
genes. For all the tested genes, fold changes in expression were
consistent in direction compared with the microarray results
except in adipose tissue for IL-15 (P  0.3), epidermal growth
factor receptor (EGFR, P  0.10), and ANG1 (P  0.09)
despite substantial Log2 fold changes of 0.49 for IL-15, 0.64
for EGFR and 0.66 for ANG1, in liver for ACLS3 (P  0.09)
and FABP3 (P  0.09) with Log2 fold changes of 0.46 and
0.60, respectively, and in hypothalamic tissue for phospho-
diesterase 4D, cAMP-specific (PDE4D, P  0.01), galactosyl-
ceramiase (P  0.3), and symplekin (SYMP, P  0.2) with
Log2 fold changes of 0.52, 0.33, and 0.52, respectively.
Overall, the results obtained from microarray were statistically
confirmed for 70% of the tested genes in the hypothalamus,
liver, and fat by qPCR.
MC4R Effects on Expression of Genes in Adipose Tissue,
Liver, and Hypothalamus
A total of 5,066 transcripts were identified to be differen-
tially expressed (q  0.07, P  0.015) in adipose tissue, with
3,276 being upregulated and 1,790 downregulated. In liver,
249 transcripts were identified to be differentially expressed
(q  0.07, P  0.001), of which 163 were upregulated and 86
downregulated. In hypothalamic tissue, 278 transcripts were
identified as differentially expressed (q  0.07, P  0.001),
with 56 being upregulated and 222 downregulated. For sim-
plicity, changes in RNA levels detected by these probe sets will
be referred to as gene expression differences. The gene-by-
gene analysis that was conducted identified evidence of effects
of the MC4R genotype (290, 41, 1, transcripts identified,
respectively) and an interaction between genotype  treatment
(1,724, 40, 2 transcripts identified, respectively) at q  0.07.
Interaction of Genotype  Treatment in Adipose Tissue,
Liver, and Hypothalamus
Animals were used in each combination of experimental
factors (n  6/genotype/treatment); every effort was made to
balance the design by assigning animals with similar weight
and sex distribution to each group to avoiding potential con-
founding with genotype by treatment interaction. On the basis
of stringent significance levels, several genes showed a clear
genotype  treatment interaction in food intake at 12 and 24 h
after MSH injection, for all three tissues considered in this
study. In fact, 1,724, 40, and 2 genotype  treatment interac-
tions were detected for adipose tissue, liver, and hypothalamus,
respectively. To further investigate these interactions, espe-
cially for adipose tissue and liver, we profiled the expression of
some genes with significant interaction using both the normal-
ization PM data and the correspondent LSMEANS obtained
during the statistical analysis. For all nine selected genes (5 for
adipose tissue and 4 for liver) a clear interaction was observed
using normalized PM and LSMEANS (Figs. 2 and 3 and
Supplementary Figs. S4 and S5, Supplementary Tables S6 and
S7).1 These results suggest a real genetic control of gene
expression sensitivity to MSH treatment that could indicate a
difference in genetic background for these and for the three
genotypes considered in this study. The large number of
significant interactions between MSH treatment and MC4R
genotype observed for adipose tissue demonstrates its dy-
namic and complex role in the regulation of food intake.
Biological Processes Affected by NDP-MSH Treatment in
the Hypothalamus, Liver, and Adipose Tissue
To identify biological processes that respond to ICV admin-
istration of NDP-MSH, differentially expressed genes in hy-
pothalamic, liver, and fat tissue were analyzed for overrepre-
sentation in GO Biological Process categories and KEGG
biological pathways (Supplementary Figs. S4 and S5, Supple-
1 The online version of this article contains supplemental material.
Table 2. Microarray data validation on a subset of
differentially expressed genes (q  0.07) by qPCR in liver,
hypothalamus, and adipose tissue
Gene Symbol
Microarray qPCR
Log 2 Fold Change P Value Ratio P Value
1Liver
ACSL3 0.463 2.29E-04 1.239 9.23E-02
FABP3 0.614 3.51E-04 1.260 9.20E-02
GALC 0.486 5.61E-04 1.520 7.00E-03
NQO1 0.920 4.87E-04 1.149 2.40E-03
MDH1 0.275 2.61E-04 1.270 2.00E-03
COX7C 0.335 3.12E-04 1.253 2.00E-02
ARL3 0.357 3.92E-05 1.280 1.00E-03
2Hypothalamus
GALC 0.333 3.96E-06 1.290 3.21E-01
KPNA4 0.269 1.62E-06 1.350 7.00E-03
NPY 0.738 8.61E-03 2.326 1.31E-02
SLC1A1 0.172 6.30E-04 1.293 2.30E-02
PDE4D 0.522 6.05E-05 1.339 1.06E-02
PRKG1 0.853 1.01E-07 1.242 6.02E-02
SYMPK 0.517 1.16E-05 1.626 1.98E-01
1Adipose Tissue
FASN 1.162 2.06E-06 2.513 0.001
LPL 0.566 6.51E-07 1.745 0.001
UCP3 0.595 3.47E-05 1.640 8.00E-03
3B-HSD 0.594 2.08E-05 2.523 9.00E-03
LEP 0.817 2.29E-06 2.421 2.40E-02
ANGPTL4 1.4128 3.88E-08 1.830 1.80E-02
ANG1 0.657 3.15E-07 1.275 8.90E-02
IL-15 0.491 3.72E-06 1.113 3.55E-01
EGFR 0.636 8.15E-06 1.233 1.00E-01
1n  36; 2n  32. Official gene symbols: ACSL3, acyl-CoA synthetase
long-chain family member 3; ANG1, angiopoietin-1; ANGPTL4, angiopoi-
etin-like-4; ARL3, ADP-ribosylation factor-like 3; COX7C, cytochrome c
oxidase subunit VIIc; EGFR, epidermal growth factor receptor; FABP3, fatty
acid binding protein 3; FASN, fatty acid synthase; GALC, galactosylcerami-
dase; 3B-HSD, hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid
delta-isomerase 1; IL-15, interleukin 15; KPNA4, karyopherin alpha 4; LEP,
leptin; LPL, lipoprotein lipase; MDH1, malate dehydrogenase 1, NAD; NPY,
neuropeptide Y; PDE4D, phosphodiesterase 4D, cAMP-specific; PRKG1, protein
kinase, cGMP-dependent, type I; SYMPK, symplekin; NQO1, NAD(P)H dehy-
drogenase, quinone 1; SLC1A1, solute carrier family 1 member 1; UCP3, uncou-
pling protein 3.
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mentary Tables S6–S12). In addition, the KEGG biological
pathway database was used to identify specific biological
pathways overrepresented by genes that responded to NDP-
MSH treatment in the hypothalamus, liver, and fat (P  0.05,
Tables 3–5). Results are described further in following sec-
tions.
NDP-MSH Effects on Hypothalamic and Liver Gene
Expression
Hypothalamic tissue underwent significant downregula-
tion of transcriptional changes in response to NDP-MSH.
Major groups of genes associated with biopolymer metab-
olism, cyclic nucleotide metabolism, and protein amino acid
phosphorylation were downregulated. In particular, genes
involved in cell communication, nucleotide metabolism,
signal transduction, amino acid metabolism, and lipid me-
tabolism were predominantly downregulated (Table 3 and
Supplementary Table S8).
The extent of significant downregulated transcriptional reg-
ulation changes in liver tissue was considerable and involved
genes associated with lipid biosynthesis and glucose catabo-
lism. The genes found to be differentially regulated in liver and
overrepresented (P  0.05) in KEGG pathways were identi-
fied (Table 4 and Supplementary Table S9). Of the 15 genes
annotated by KEGG to encode for enzymes and binding
proteins in lipid biosynthesis, the majority were downregu-
lated, including the rate-limiting FABP1–3 involved in the
peroxisome proliferator-activated receptor (PPAR) signal-
ing pathway. In addition, genes involved in nucleotide
metabolism, amino acid metabolism, and energy metabo-
lism, such as carbonic anhydrase III (CA3) and COX7C,
were downregulated (Table 4). Genes associated with glu-
coneogenesis, lactate dehydrogenase-C, glycan biosynthe-
sis, and metabolism were upregulated (Table 4).
In liver tissue the effect of genotype in the response to
MSH was not as robust as observed in adipose tissue; GO
enrichment cluster analysis for genotype did not detect any
cluster themes.
Effects of MSH Treatment on Adipose Tissue
The scope of the significant downregulated transcriptional
regulation changes in adipose tissue was considerable and
surprising and involved major groups of genes associated
with both anabolic and catabolic processes. In particular,
genes involved in direct energy-generating processes such
as oxidative phosphorylation, electron transport, ATP syn-
thesis, and the citric acid cycle (TCA) were prominently
downregulated in NDP-MSH-treated pigs (Table 5 and Sup-
plementary Table S10). Our data also indicate a metabolic switch
toward energy conservation since genes involved in energy-
intensive biosynthetic and catabolic processes were downregu-
lated in MSH-treated pigs. This included genes encoding biosyn-
thetic pathways such as steroid and lipid biosynthesis, fatty acid
synthesis, protein translation, amino acid synthesis, and ubiqui-
none biosynthesis, as well as genes encoding enzymes involved in
catabolic processes such as proteolysis, amino acid degradation,
and pyruvate metabolism. In particular, downregulation of genes
Fig. 3. Liver tissue gene expression profiles for cytochrome c oxidase subunit
VIIc (COX7C) and isocitrate dehydrogenase 3 alpha (IDH3A) that exhibited a
genotype  treatment interaction (P  0.0001). Values in the y-axis are
LSMEAN (n  6/genotype/treatment). Black bars represent saline controls,
and gray bars represent NDP-MSH treatment.
Fig. 2. Adipose tissue gene expression profiles for acyl-CoA synthetase
long-chain family member 3 (ACSL3) and integrin alpha 6 (ITGA6) with a
genotype  treatment interaction (P  0.0001). Values in the y-axis are
LSMEAN (n  6/genotype/treatment). Black bars represent saline controls,
and gray bars represent NDP-MSH treatment.
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Table 3. Hypothalamus tissue genes with false discovery rate correction (q-value) cutoff 0.07
KEGG Pathway Theme/Gene Name* Gene Symbol Porcine Affy ID Log2 Fold Change P Value q-value
Amino Acid Metabolism
Glutamate-cysteine ligase, modifier subunit GCLM Ssc.24693.2.S1_at 0.328 5.69E-05 2.45E-02
Branched chain aminotransferase 1, cytosolic BCAT1 Ssc.27431.1.A1_at 0.295 2.60E-05 1.74E-02
Tyrosyl-tRNA synthetase YARS Ssc.16687.1.S1_at 0.142 4.36E-04 5.46E-02
Myst histone acetyltransferase (monocytic leukemia) 4 MYST4 Ssc.30919.1.A1_at 0.189 2.74E-04 4.56E-02
Methylcrotonoyl-coenzyme A Carboxylase 2 (beta) MCCC2 Ssc.27572.1.S1_at 0.209 5.74E-05 2.43E-02
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 PLOD2 Ssc.24126.1.A1_at 0.232 6.45E-04 6.30E-02
Serine hydroxymethyltransferase 1 (soluble) SHMT1 Ssc.23145.1.A1_at 0.322 5.71E-04 6.12E-02
Kiaa0828 protein KIAA0828 Ssc.12833.1.A1_at 0.411 1.11E-04 2.97E-02
Carbohydrate Metabolism
Tissue-specific transplantation antigen P35B TSTA3 Ssc.18627.1.S1_a_at 0.172 4.02E-04 5.25E-02
Swi/Snf-related, matrix-associated, actin-dependent
regulator of chromatin, subfamily A, member 2 SMARCA2 Ssc.1339.1.A1_at 0.160 7.62E-04 6.81E-02
Inositol polyphosphate multikinase IPMK Ssc.18803.1.S1_at 0.205 3.55E-04 5.01E-02
Chitobiase, Di-N-acetyl- CTBS Ssc.13500.1.A1_at 0.243 9.09E-05 2.89E-02
Cell Communication
Protein kinase, cGMP-dependent, type I PRKG1 Ssc.10791.1.A1_at 0.853 1.01E-07 1.22E-03
Protein kinase C, Iota PRKCI Ssc.7253.1.A1_at 0.304 2.17E-04 4.21E-02
Membrane-associated guanylate kinase, Ww And Pdz
domain containing 2 MAGI2 Ssc.17432.1.S1_at 0.165 4.40E-04 5.44E-02
Laminin, alpha 2 (merosin, congenital muscular
dystrophy) LAMA2 Ssc.12029.1.S1_at 0.179 7.99E-04 6.96E-02
Myosin, heavy polypeptide 4, skeletal muscle MYH4 Ssc.30625.1.S1_at 0.204 9.50E-05 2.86E-02
Protein kinase C, epsilon PRKCE Ssc.8482.1.A1_at 0.232 6.98E-04 6.47E-02
Caveolin 1, caveolae protein, 22 kDa CAV1 Ssc.24958.1.A1_at 0.242 2.08E-04 4.17E-02
Integrin, alpha 6 ITGA6 Ssc.14294.1.A1_at 0.279 1.44E-04 3.48E-02
Keratin 10 (epidermolytic hyperkeratosis; keratosis
palmaris et plantaris) KRT10 Ssc.9782.1.A1_at 0.299 8.27E-07 3.32E-03
Symplekin SYMPK Ssc.26722.1.S1_at 0.517 1.16E-05 1.22E-02
Cell Growth and Death
Cell division cycle 27 CDC27 Ssc.27075.1.A1_at 0.299 5.56E-04 6.04E-02
Cyclin H CCNH Ssc.26385.1.S1_at 0.158 1.16E-04 3.02E-02
Cytochrome C, somatic CYCS Ssc.17412.1.A1_at 0.159 7.04E-04 6.51E-02
Development
Unc-5 homolog C (C. elegans) UNC5C Ssc.10672.1.A1_at 0.179 2.87E-04 4.49E-02
Actin-binding Lim protein 1 ABLIM1 Ssc.9560.2.S1_a_at 0.193 2.54E-04 4.42E-02
Ssc.10988.1.S1_at 0.262 5.82E-04 6.11E-02
Ssc.19823.1.A1_at 0.267 6.34E-05 2.43E-02
Endocrine System
Exocyst complex component 7 EXOC7 Ssc.22063.1.S1_at 0.232 6.94E-04 6.49E-02
Energy Metabolism
Cox15 homolog, cytochrome c oxidase assembly protein
(yeast) COX15 Ssc.22105.1.S1_at 0.139 6.58E-04 6.38E-02
ATP synthase, H transporting, mitochondrial F1
complex, beta polypeptide ATP5B Ssc.18170.1.S1_at 0.289 1.94E-05 1.56E-02
Folding, Sorting, and Degradation
Golgi snap receptor complex member 2 GOSR2 Ssc.28472.1.S1_at 0.272 4.00E-06 6.04E-03
Syntaxin 18 STX18 Ssc.26658.1.A1_at 0.137 2.18E-04 4.18E-02
Glycan Biosynthesis and Metabolism
Dehydrodolichyl diphosphate synthase DHDDS Ssc.24439.1.A1_at 0.161 5.21E-05 2.37E-02
O-linked N-Acetylglucosamine (Glcnac) transferase (Udp-
N-acetylglucosamine:polypeptide-N-acetylglucosaminyl
transferase) OGT Ssc.8000.1.A1_at 0.140 4.62E-04 5.57E-02
Exostoses (multiple) 1 EXT1 Ssc.7562.1.A1_at 0.167 2.80E-04 4.51E-02
Mannosidase, alpha, class 1A, member 1 MAN1A1 Ssc.15489.1.S1_at 0.324 1.61E-04 3.67E-02
Uronyl-2-sulfotransferase UST Ssc.29402.1.A1_at 0.399 9.61E-05 2.86E-02
Infectious Diseases
Ero1-like (S. cerevisiae) ERO1L Ssc.2709.1.S1_at 0.343 1.22E-04 3.10E-02
Continued
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involved in glucose catabolism represented one of the single
largest GO enrichment cluster themes that was downregulated and
included metabolism and catabolism of very simple and comp-
lex carbohydrates (Supplementary Table S10). However, genes
involved in cofactor metabolism represented the largest GO en-
richment cluster theme and included biosynthesis and metabolism
of nucleotides, nucleosides, and ATP (Supplementary Table S10).
The fold changes, q, and P values of genes involved in MSH-
Table 3.—Continued
KEGG Pathway Theme/Gene Name* Gene Symbol Porcine Affy ID Log2 Fold Change P Value q-value
Lipid Metabolism
Cdp-diacylglycerol–inositol 3-phosphatidyltransferase
(phosphatidylinositol synthase) CDIPT Ssc.21033.2.S1_at 0.243 2.19E-04 4.17E-02
Sterol O-acyltransferase (acyl-coenzyme A: cholesterol
acyltransferase) 1 SOAT1 Ssc.5643.1.A1_at 0.208 3.72E-04 5.13E-02
Stearoyl-CoA desaturase 5 SCD5 Ssc.14373.1.A1_at 0.219 8.05E-04 6.98E-02
Glycerol-3-phosphate dehydrogenase 1-like GPD1L Ssc.24184.1.S1_at 0.236 1.67E-05 1.44E-02
Phospholipase D1, phosphatidylcholine-specific PLD1 Ssc.7156.1.A1_at 0.246 2.28E-04 4.20E-02
Elovl family member 5, elongation of long chain fatty
acids (Fen1/Elo2, Sur4/Elo3-like, yeast) ELOVL5 Ssc.25062.1.A1_at 0.270 4.75E-04 5.59E-02
Galactosylceramidase GALC Ssc.30293.1.A1_at 0.333 3.96E-06 6.36E-03
Membrane Transport
ATP-binding cassette, subfamily C (Cftr/Mrp), member 5 ABCC5 Ssc.6425.1.A1_at 0.252 3.96E-04 5.21E-02
Metabolism of Other Amino Acids
Selenophosphate synthetase 1 SEPHS1 Ssc.22824.1.S1_at 0.232 1.67E-04 3.69E-02
Neurodegenerative Diseases
Arginine-glutamic acid dipeptide (re) repeats RERE Ssc.5095.1.A1_at 0.378 8.58E-07 2.96E-03
Nucleotide Metabolism
Uridine-cytidine kinase 2 UCK2 Ssc.24728.2.S1_at 0.216 7.82E-04 6.83E-02
Adenylate cyclase 7 ADCY7 Ssc.5048.1.S1_at 0.144 5.32E-04 5.95E-02
Phosphodiesterase 8A PDE8A Ssc.29579.1.A1_at 0.208 6.64E-05 2.50E-02
5=-Nucleotidase, ecto (Cd73) NT5E Ssc.6013.1.A1_at 0.314 2.34E-06 5.13E-03
Phosphodiesterase 8A PDE8A Ssc.4651.1.S1_at 0.352 2.72E-04 4.55E-02
Phosphodiesterase 4D, cAMP-specific (phosphodiesterase
e3 dunce homolog, Drosophila) PDE4D Ssc.17233.1.A1_at 0.522 6.05E-05 2.35E-02
Sensory System
Adrenergic, beta, receptor kinase 2 ADRBK2 Ssc.9883.1.A1_at 0.311 3.27E-05 1.92E-02
Signal Transduction
Mitogen-activated protein kinase 1 MAPK1 Ssc.5106.1.S1_at 0.215 3.50E-04 4.96E-02
Purinergic receptor P2X, ligand-gated ion channel, 4 P2RX4 Ssc.18377.1.S1_at 0.137 9.31E-05 2.88E-02
Nuclear factor of activated T cells 5, tonicity-responsive NFAT5 Ssc.17745.1.S1_at 0.178 1.03E-04 2.95E-02
Calcium channel, voltage-dependent, gamma subunit 8 CACNG8 Ssc.18270.1.S1_at 0.201 3.22E-04 4.79E-02
Neuregulin 3 NRG3 Ssc.13323.2.S1_at 0.203 6.77E-04 6.46E-02
Mitogen-activated protein kinase kinase kinase kinase 4 MAP4K4 Ssc.3574.1.A1_at 0.210 6.19E-04 6.33E-02
Phosphoinositide-3-kinase, regulatory subunit 1 (P85
alpha) PIK3R1 Ssc.10754.1.A1_at 0.232 2.75E-04 4.52E-02
V-Erb-A erythroblastic leukemia viral oncogene homolog
4 (avian) ERBB4 Ssc.25003.1.S1_at 0.258 2.08E-04 4.15E-02
Bone morphogenetic protein 5 BMP5 Ssc.1179.1.S1_at 0.312 5.80E-05 2.41E-02
Mitogen-activated protein kinase kinase kinase 14 MAP3K14 Ssc.13241.1.A1_at 0.334 1.22E-04 3.08E-02
Fibroblast growth factor receptor 2 FGFR2 Ssc.7516.1.A1_at 0.344 5.21E-04 5.87E-02
Neuregulin 1 NRG1 Ssc.4398.1.S1_at 0.354 9.17E-06 1.16E-02
DNA damage-inducible transcript 4 DDIT4 Ssc.4104.1.S1_at 0.377 1.86E-07 1.49E-03
Latent transforming growth factor beta binding protein 1 LTBP1 Ssc.8072.1.A1_at 0.591 2.49E-05 1.77E-02
Signaling Molecules and Interaction
Myelin protein zero-like 1 MPZL1 Ssc.30671.1.A1_at 0.290 7.58E-04 6.83E-02
Ssc.21255.1.S1_at 0.236 5.44E-04 5.97E-02
Glutamate receptor, ionotropic, kainate 2 GRIK2 Ssc.4849.1.A1_at 0.242 3.78E-04 5.16E-02
Xenobiotics Biodegradation and Metabolism
Sirtuin (silent mating type information regulation 2
homolog) 1 (S. cerevisiae) SIRT1 Ssc.10786.1.A1_at 0.283 1.02E-04 3.01E-02
Epoxide hydrolase 1, microsomal (xenobiotic) EPHX1 Ssc.15309.1.S1_at 0.279 1.16E-04 2.99E-02
*KEGG Pathways were found using DAVID’s Functional Annotation tool; Gene names and symbols are the human homologs of porcine genes from the
Affymetrix (Affy) array probes (67).
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Table 4. Liver tissue genes with false discovery rate correction (q-value) cutoff 0.07
KEGG Pathway Theme/Human Gene Name* Gene Symbol Porcine Affy ID Log2 Fold Change P Value q-value
Amino Acid Metabolism
Methionine adenosyltransferase i, alpha MAT1A Ssc.27380.1.S1_at 0.391 3.28E-04 5.28E-02
Nuclear receptor binding set domain protein 1 NSD1 Ssc.20770.1.S1_at 0.191 2.43E-04 4.59E-02
Phosphoserine phosphatase PSPH Ssc.12475.1.A1_at 0.667 2.16E-04 4.53E-02
Carbohydrate Metabolism
Lactate dehydrogenase C LDHC Ssc.302.1.S1_at 0.251 6.56E-04 6.85E-02
Phospholipase C, gamma 2 (phosphatidylinositol-specific) PLCG2 Ssc.24329.1.A1_at 0.231 9.14E-05 3.20E-02
Transaldolase 1 TALDO1 Ssc.1050.1.S1_at 0.169 4.69E-04 6.12E-02
Malate dehydrogenase 1, Nad (soluble) MDH1 Ssc.11103.1.S1_at 0.275 2.61E-04 4.77E-02
Cancers
Egl nine homolog 1 (C. elegans) EGLN1 Ssc.5854.1.S1_at 0.195 1.84E-04 4.59E-02
Baculoviral Iap repeat-containing 5 (survivin) BIRC5 Ssc.432.1.S1_at 0.383 9.03E-05 3.20E-02
Cell Communication
Multiple Pdz domain protein MPDZ Ssc.23933.1.A1_at 0.491 2.84E-05 1.56E-02
Ssc.5448.1.S1_at 0.486 2.84E-04 5.04E-02
Tubulin, beta 2A TUBB2A Ssc.10115.3.S1_a_at 0.370 2.76E-05 1.55E-02
Tubulin, beta TUBB Ssc.6903.1.S2_at 0.385 5.55E-04 6.59E-02
Tubulin, alpha, ubiquitous TUBA1C Ssc.17154.1.A1_a_at 0.457 3.03E-04 5.18E-02
Tubulin, beta TUBB Ssc.6903.1.S1_at 0.497 6.70E-04 6.79E-02
Cell Growth and Death
Retinoblastoma-like 2 (P130) RBL2 Ssc.10727.1.A1_at 0.205 6.05E-04 6.70E-02
Cdc6 cell division cycle 6 homolog (S. cerevisiae) CDC6 Ssc.11879.1.A1_at 0.419 3.83E-05 1.88E-02
Cell Motility
Rho guanine nucleotide exchange factor (Gef) 7 ARHGEF7 Ssc.17929.1.A1_at 0.249 1.05E-04 3.42E-02
Energy Metabolism
Atp Synthase, H transporting, mitochondrial F0 complex,
subunit C3 (subunit 9) ATP5G3 Ssc.13371.1.S1_at 0.166 5.72E-04 6.70E-02
Cytochrome c oxidase subunit VIIC COX7C Ssc.1461.1.S1_at 0.335 3.12E-04 5.23E-02
Carbonic anhydrase III, muscle specific CA3 Ssc.10960.1.S1_at 0.961 3.95E-04 5.64E-02
Ssc.19866.1.S1_at 1.061 2.47E-06 4.96E-03
Folding, Sorting, and Degradation
Unc-51-like kinase 2 (C. elegans) ULK2 Ssc.18729.1.A1_s_at 0.211 7.33E-06 9.30E-03
Glycan Biosynthesis and Metabolism
N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2 NDST2 Ssc.6316.1.S1_at 0.163 1.01E-04 3.34E-02
Cdc91 cell division cycle 91-like 1 (S. cerevisiae) PIGU Ssc.22132.1.A1_at 0.151 5.09E-04 6.33E-02
Immune System
Toll-like receptor 6 TLR6 Ssc.22011.1.S1_at 0.235 3.69E-04 5.57E-02
Complement component 3 C3 Ssc.23205.2.A1_at 0.173 2.37E-04 4.66E-02
Coagulation factor IX (plasma thromboplastic component,
christmas disease, hemophilia B) F9 Ssc.10446.2.S1_at 0.102 2.99E-04 5.20E-02
Lipid Metabolism
Galactosylceramidase GALC Ssc.7531.1.A1_at 0.486 5.61E-04 6.63E-02
Galactosylceramidase GALC Ssc.7531.2.S1_at 0.469 3.86E-04 5.62E-02
Ethanolamine kinase 2 ETNK2 Ssc.3730.1.S1_at 0.297 6.65E-04 6.80E-02
Phosphatidic acid phosphatase type 2B PPAP2B Ssc.6233.1.S1_at 0.242 4.48E-04 6.10E-02
Hypothetical gene supported by Ak002212; Ak022822;
Bc006985; Nm_018396 METTL2A Ssc.5449.1.S1_at 0.123 4.83E-04 6.23E-02
Phosphatidylserine synthase 2 PTDSS2 Ssc.3608.1.S1_at 0.119 5.97E-04 6.67E-02
Sterol O-acyltransferase (acyl-coenzyme A: cholesterol
acyltransferase) 1 SOAT1 Ssc.19509.1.A1_at 0.201 4.57E-04 6.13E-02
Putative methyltransferase WBSCR22 Ssc.10992.1.S1_a_at 0.224 5.30E-04 6.46E-02
Elovl family member 5, elongation of long chain fatty acids
(Fen1/Elo2, Sur4/Elo3-like, yeast) ELOVL5 Ssc.1151.1.A1_at 0.238 2.42E-04 4.60E-02
Platelet-activating factor acetylhydrolase 2, 40 kDa PAFAH2 Ssc.2768.3.S1_at 0.296 6.96E-04 6.83E-02
Acyl-CoA synthetase long-chain family member 3 ACSL3 Ssc.2176.1.A1_at 0.463 2.29E-04 4.64E-02
Hydroxysteroid (17-beta) dehydrogenase 7 HSD17B7 Ssc.12454.1.A1_at 0.514 2.06E-04 4.60E-02
Fatty acid binding protein 1, liver* FABP1 Ssc.604.1.S1_at 0.279 2.71E-05 1.56E-02
Continued
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nduced changes in carbohydrate and energy metabolism are summa-
rized in Table 5. Other significant GO enrichment cluster themes
include carboxylic acid metabolism, sterol biosynthesis, and cellular
catabolism, among others (Supplementary Table S10).
The scope of the significantly upregulated transcriptional
regulation changes in adipose tissue was considerably less than
downregulated transcriptional regulation but also involved ma-
jor groups of genes associated with both anabolic and catabolic
processes (Supplementary Table S11). Genes involved in
DNA-dependent transcription were upregulated as were genes
involved in regionalization development, regionalization, de-
termination of bilateral symmetry, and cell communication.
Additionally, genes that regulate apoptosis and neuron apopto-
sis in particular were also upregulated in adipose tissue (Table
5 and Supplementary Table S11).
Although the effects of the MC4R genotype in response to
MSH identified 290 genes in adipose tissue, GO enrichment
cluster analysis only identified one cluster theme nucleocyto-
plasmic transport with an enrichment score of 1.3 or greater
(Supplementary Table S12).
DISCUSSION
Our results demonstrate for the first time in a large domestic
animal that central administration of melanocortin receptor
agonist NDP-MSH resulted in differentially regulated gene
expression in hypothalamus, liver, and adipose tissue. It should
be noted that although changes in RNA expression do not
always correspond to changes in protein expression or biolog-
ical response, we suggest that systemic changes in the expres-
sion of genes that belong to overrepresented GO or KEGG
categories imply a functional change. Although the response in
gene expression to NDP-MSH suggests melanocortin system
involvement, further work is needed substantiate this hypoth-
esis.
The effect of genotype on the response to NDP-MSH was
markedly greater in the number genes differentially regulated
for adipose tissue compared with hypothalamus or liver tissue,
although feeding response to MC4R agonist was similar across
genotypes. We have previously reported that adipose tissue is
innervated by adrenergic nerve fibers (34). Moreover, immu-
nocytochemical data revealed that most of the subpopulations
of the adrenergic leptin receptor-immunoreactive neurons sup-
plying fat tissue in the pig that were positive for NPY and
tyrosine hydroxylase immunoactivity (17) were located in the
paraventricular nucleus, ventromedial nucleus, anterior hypo-
thalamic area, preoptic area, arcuate nucleus, and supraoptic
nucleus (16). Thus, it is conceivable that these neurons also
expressed MC4R and central administration of NDP-MSH may
Table 4.—Continued
KEGG Pathway Theme/Human Gene Name* Gene Symbol Porcine Affy ID Log2 Fold Change P Value q-value
Fatty acid binding protein 3, muscle and heart (mammary-
derived growth inhibitor)* FABP3 Ssc.4360.1.A1_at 0.614 3.51E-04 5.46E-02
NAD(P)H dehydrogenase, quinone 1 NQO1 Ssc.1142.1.S1_at 0.920 4.87E-04 6.25E-02
Membrane Transport
ATP-binding cassette, subfamily C (Cftr/Mrp), member 5 ABCC5 Ssc.6425.3.A1_at 0.313 1.79E-05 1.35E-02
Metabolism of Cofactors and Vitamins
Nicotinamide nucleotide adenylyltransferase 3 NMNAT3 Ssc.7092.1.A1_at 0.330 2.00E-04 4.65E-02
Aldehyde dehydrogenase 1 family, member A1 ALDH1A1 Ssc.6928.1.A1_at 0.152 5.61E-04 6.60E-02
Aldehyde dehydrogenase 1 family, member A1 ALDH1A1 Ssc.24986.1.S1_at 0.248 5.27E-04 6.46E-02
Nucleotide Metabolism
Phosphodiesterase 6D, cGMP-specific, rod, delta PDE6D Ssc.19724.2.S1_at 0.181 1.10E-04 3.49E-02
Nonmetastatic cells 1, protein (Nm23A) expressed in NME1 Ssc.19546.1.S1_at 0.260 1.14E-06 4.60E-03
Ribonucleotide reductase M2 polypeptide RRM2 Ssc.7111.1.A1_at 0.808 1.71E-04 4.44E-02
Signaling Molecules and Interaction
Hypocretin (orexin) receptor 2 HCRTR2 Ssc.25690.1.S1_at 0.279 2.57E-05 1.55E-02
Activin A receptor, type IIB ACVR2B Ssc.24084.1.A1_at 0.193 6.61E-04 6.79E-02
Hyaluronan-mediated motility receptor (Rhamm) HMMR Ssc.26770.1.S1_at 0.521 1.04E-05 1.05E-02
Signal Transduction
Frizzled homolog 1 (Drosophila) FZD1 Ssc.3590.1.A1_at 0.308 1.83E-05 1.30E-02
Wingless-type Mmtv integration site family, member 9B WNT9B Ssc.26099.1.S1_at 0.232 9.01E-06 1.03E-02
Purinergic receptor P2X, ligand-gated ion channel, 4 P2RX4 Ssc.18377.1.S1_at 0.214 4.58E-04 6.11E-02
Purinergic receptor P2X, ligand-gated ion channel, 4 P2RX4 Ssc.18377.3.S1_at 0.215 2.59E-07 1.56E-03
Purinergic receptor P2X, ligand-gated ion channel, 4 P2RX4 Ssc.18377.3.S1_a_at 0.308 2.30E-04 4.61E-02
Stathmin 1/oncoprotein 18 STMN1 Ssc.7701.1.A1_at 0.660 1.89E-04 4.65E-02
Translation
Ribosomal protein L31 RPL31 Ssc.27023.1.S1_at 0.165 2.41E-04 4.68E-02
Xenobiotics Biodegradation and Metabolism
Acid phosphatase 5, tartrate resistant ACP5 Ssc.575.1.S1_at 0.374 1.90E-04 4.59E-02
*KEGG Pathways were found using DAVID’s Functional Annotation tool; Gene names and symbols are the human homolog of porcine genes from the
Affymetrix array probes (67).
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Table 5. Fat tissue genes with the top 50-fold change
KEGG Pathway Theme/Gene Name* Gene Symbol Porcine Affy ID Log2 Fold Change P Value q-value
Amino Acid Metabolism
Rap guanine nucleotide exchange factor (Gef) 4 RAPGEF4 Ssc.22583.1.S1_at 0.721 5.60E-08 1.44E-05
Catechol-O-methyltransferase COMT Ssc.785.3.S1_at 0.703 4.95E-08 1.39E-05
Aldehyde dehydrogenase 4 family, member A1 ALDH4A1 Ssc.5607.1.S1_at 0.840 4.43E-06 1.92E-04
Carbohydrate Metabolism
Phosphoenolpyruvate carboxykinase 1 (soluble) PCK1 Ssc.22959.1.S1_at 1.394 8.59E-06 2.97E-04
Citrate lyase beta like CLYBL Ssc.1137.1.S1_at 0.863 6.63E-04 7.23E-03
Hexokinase 1 HK1 Ssc.5615.1.S1_at 0.695 2.16E-07 2.93E-05
Aldehyde dehydrogenase 1 family, member B1 ALDH1B1 Ssc.25096.1.A1_at 0.710 1.68E-04 2.61E-03
Transaldolase 1 TALDO1 Ssc.1050.1.S1_at 0.716 8.62E-10 2.31E-06
Aconitase 1, soluble ACO1 Ssc.4767.1.S1_at 0.763 6.52E-07 5.60E-05
Pyruvate kinase, muscle PKM2 Ssc.1035.1.S1_at 0.799 1.49E-06 9.48E-05
Dihydrolipoamide S-acetyltransferase (E2 component of
pyruvate dehydrogenase complex) DLAT Ssc.14.1.S1_at 0.922 1.68E-07 2.49E-05
Pyruvate dehydrogenase (lipoamide) beta PDHB Ssc.4382.1.S1_at 1.160 2.03E-08 8.92E-06
Malic enzyme 1, NADP()-dependent, cytosolic ME1 Ssc.16336.1.S1_at 1.230 6.89E-08 1.53E-05
Hexokinase 2 HK2 Ssc.3509.1.S1_at 1.579 7.18E-10 2.17E-06
Acyl-CoA synthetase short-chain family member 2 ACAS2 Ssc.27871.1.S1_at 1.648 7.54E-09 5.87E-06
ATP citrate lyase ACLY Ssc.30707.1.S1_at 1.909 9.43E-08 1.79E-05
Cell Communication
Laminin, alpha 2 (merosin, congenital muscular dystrophy) LAMA2 Ssc.11815.1.A1_s_at 0.710 5.79E-06 2.23E-04
Cell Motility
Actin, alpha 2, smooth muscle, aorta ACTG2 Ssc.10316.1.S1_at 0.680 8.08E-03 4.54E-02
Cell Growth and Death
Cytochrome c, somatic CYCS Ssc.6694.1.S1_at 0.672 6.46E-07 5.60E-05
Energy Metabolism
Sulfotransferase family, cytosolic, 1A, phenol-preferring,
member 3 SULT1A1 Ssc.20006.1.S1_at 1.278 1.76E-06 1.08E-04
Cytochrome c-1 CYC1 Ssc.886.1.S1_at 0.679 1.23E-08 6.62E-06
NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75 kDa
(NADH-coenzyme Q reductase) NDUFS1 Ssc.10953.1.A1_at 0.702 5.03E-08 1.38E-05
Ubiquinol-cytochrome c Reductase, Rieske iron-sulfur
polypeptide 1 UQCRFS1 Ssc.1854.1.A1_at 0.709 5.56E-08 1.46E-05
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3,
12 kDa NDUFB3 Ssc.20297.1.S1_at 0.746 1.06E-08 6.42E-06
ATP synthase, H transporting, mitochondrial F0 complex,
subunit C1 (subunit 9) ATP5G1 Ssc.1649.1.A1_at 0.789 5.81E-08 1.42E-05
Ubiquinol-cytochrome c reductase, complex III subunit VII,
9.5 kDa UCRQ_HUMAN Ssc.17272.1.A1_at 0.811 8.73E-09 6.58E-06
Carbonic anhydrase III, muscle specific CA3 Ssc.10960.1.S1_at 0.842 4.18E-03 2.78E-02
Glycan Biosynthesis and Metabolism
Peptidoglycan recognition protein 2 PGLYRP2 Ssc.16628.1.S1_at 0.745 2.29E-03 1.77E-02
Lipid Metabolism
Angiopoietin-like 4† ANGPTL4 Ssc.8980.1.A1_at 1.413 3.88E-08 1.19E-05
Dehydrogenase/reductase (Sdr family) member 4 DHRS4 Ssc.86.1.S1_at 0.816 7.01E-05 1.39E-03
Carnitine palmitoyltransferase 1A (liver) CPT1A Ssc.8974.1.S1_at 0.676 4.44E-09 4.28E-06
24-Dehydrocholesterol reductase DHCR24 Ssc.19298.2.S1_at 0.741 7.78E-08 1.66E-05
Hydroxysteroid (17-Beta) dehydrogenase 12 HSD17B12 Ssc.20785.1.A1_at 0.750 1.05E-08 6.52E-06
Stearoyl-CoA desaturase (delta-9-desaturase) SCD Ssc.16159.1.S1_at 0.758 1.06E-03 1.01E-02
Acetyl-coenzyme A carboxylase alpha ACACA Ssc.16018.1.S1_at 1.017 1.65E-08 7.97E-06
Emopamil binding protein (sterol isomerase) EBP Ssc.5045.1.S1_at 1.026 2.84E-09 3.26E-06
Isopentenyl-diphosphate delta isomerase 1 IDI1 Ssc.6714.1.A1_at 1.067 3.81E-09 3.99E-06
Fatty acid synthase FASN Ssc.25076.2.S1_at 1.162 2.06E-06 1.18E-04
Lipase, endothelial LIPG Ssc.21663.1.A1_at 1.271 2.51E-07 3.18E-05
Membrane Transport
ATP-binding cassette, subfamily A (Abc1), member 1 ABCA1 Ssc.7146.1.A1_at 0.731 5.68E-05 1.19E-03
Metabolism of Other Amino Acids
Glutathione peroxidase 3 (plasma) GPX3 Ssc.19694.1.S1_at 0.724 4.65E-03 3.00E-02
Continued
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have evoked sympathetic outflow to subcutaneous adipose
tissue and the subsequent differential response in gene expres-
sion observed in liver and the hypothalamus. To that extent,
Song et al. (65) reported that MC4R mRNA that was colocal-
ized in pseudorabies virus-labeled neurons with sympathetic
outflow to white adipose tissue was located in hypothalamic
paraventricular, suprachiasmatic, arcuate, and dorsomedial nu-
clei in the male hamster. Furthermore, central administration of
melanotan II (MTII), a MC3/4R agonist, resulted in differential
activation of sympathetic innervation of white and brown
adipose tissue, as measured by norepinephrine turnover and
stimulated white adipose tissue lipolysis (7). We suggest that
central administration of NDP-MSH evoked sympathetic out-
flow through activation of the MC4R. However, it should be
noted that the colocalization of MC4R with hypothalamic
neurons that innervate adipose tissue has not been determined
in the pig. Furthermore, because NPD-MSH is an MC3R and
MC4R agonist, an effect due to MC3R activation cannot be
ruled out.
Energy homeostasis is regulated by close interconnected
neuroendocrine and autonomic neural pathways emanating
from the hypothalamus as described above (64). Following
MC4R stimulation, NPY expression increased, while promela-
nin-concentrating hormone expression decreased with no
change in AGRP and POMC expression. The fact that NPY
and MSH have opposing actions in the regulation of appetite
and energy balance suggests a possible feedback regulatory
mechanism in the regulation of energy balance as previously
described by Mounien et al. (55). A notable finding in the
present study was that NDP-MSH treatment predominantly
downregulated genes involved in two major GO enrichment
cluster themes, cell communication and signal transduction.
Genes such as SYMP, which encodes for a nuclear protein that
functions in the regulation of polyadenylation and promotes
gene expression (45), and neuregulin-1 and -3, which interact
with EGFR to induce growth and differentiation of epithelial,
neuronal, and glial cells (21, 50), were downregulated. Addi-
tionally, genes involved in nucleotide metabolism were down-
regulated; two genes of interest were the phosphodiesterase
4D, cAMP-specific (PDE4D), and PDE8A. These genes play a
crucial role as terminators of the cAMP signal and restore
cellular responsiveness required for neuroendocrine cells (3).
The effect of feed deprivation on gene expression involves
metabolic adaptations to the metabolic state in different tissues
and has been previously reported for rodents (28, 41, 62).
Several adaptations occur during fasting to maintain energy
homeostasis in adipose tissue and liver. In adipose tissue,
lipolysis is increased in response to food deprivation and
therefore a breakdown of triglycerides, which results in in-
creased free fatty acid (FFA) to be utilized as an energy source
by other tissues (25). Moreover, FFA oxidation occurs at the
liver, which leads to the production of ketone bodies. In
addition, liver glycogen is utilized during the early stages of
caloric restriction (15). These events as described above lead to
eventual reprogramming of the transcriptional events that fol-
low energy deprivation. We report here that NDP-MSH ad-
ministration and subsequent activation of the melanocortin
system, a key neuronal circuit in energy homeostasis, directly
affected peripheral genes that regulated energy, lipid, and
carbohydrate metabolism in liver and adipose tissue. The most
notable effect in the liver was on genes encoding for enzymes
and binding proteins representing lipogenesis, in which nine of
the 15 genes were downregulated, such as FABP3, acyl-CoA
synthetase long-chain family member 3, and elongation of long
chain fatty acids 5. These genes play an essential role in de
novo lipid synthesis (57, 66). Moreover, genes involved in
energy metabolism, such as CA3, COX7C, and MDH1, were
also downregulated. This response to NDP-MSH is indicative
of an energy conservation response during fasting and is
similar to that reported by Lakhagvadorj et al. (49), in which
energy-generating processes such as amino acid metabolism
and lipid and steroid biosynthesis in fasted pigs expressing the
MC4R D298N variant were also downregulated. Furthermore,
recent reports demonstrated that CNS-MC3/4R directly regu-
lates hepatic glucose metabolism (58), thermogenesis in brown
adipose tissue (71), and lipolysis in white adipose tissue (7).
Moreover, the melanocortin antagonist, SHU9119, stimulated
expression of lipogenic genes, sterol regulatory element-bind-
ing protein-1C, and PPAR2, and increased lipid content in the
liver (56, 61). In contrast, ICV administration of am MC3/4R
Table 5.—Continued
KEGG Pathway Theme/Gene Name* Gene Symbol Porcine Affy ID Log2 Fold Change P Value q-value
Nucleotide Metabolism
Phosphodiesterase 5A, cGMP-specific PDE5A Ssc.30373.1.A1_at 1.047 4.24E-05 9.57E-04
Signal Transduction
Paired box gene 2 PAX2 Ssc.21096.1.S1_at 1.028 3.46E-06 1.62E-04
Mitogen-activated protein kinase 9 MAPK9 Ssc.24337.1.S1_at 0.819 6.76E-06 2.50E-04
Epidermal growth factor (beta-urogastrone) EGF Ssc.9392.3.A1_at 0.812 7.39E-06 2.66E-04
Signaling Molecules and Interaction
Major histocompatibility complex, class II, Dr beta 1 HLA-DRB4 Ssc.210.7.S1_x_at 0.888 5.95E-03 3.62E-02
Claudin 5 (transmembrane protein deleted in
velocardiofacial syndrome) CLDN5 Ssc.4227.1.S1_at 0.746 1.33E-07 2.19E-05
Major histocompatibility complex, class I, B HLA-B Ssc.18553.1.S1_at 0.743 2.57E-04 3.56E-03
Hyaluronan-mediated motility receptor (rhamm) HMMR Ssc.26770.1.S1_at 0.726 1.52E-04 2.43E-03
Leptin (obesity homolog, mouse) LEP Ssc.265.1.S2_at 0.817 2.29E-06 1.25E-04
†Angiopoietin-like 4 is not in the KEGG pathway theme Lipid Metabolism, but research shows (24a, 75) that angiopoietin-like 4 is highly involved in lipid
metabolism in human and swine models. False discovery rate correction (q-value) cutoff 0.07; *KEGG Pathways were found using DAVID’s Functional
Annotation tool; Gene names and symbols are the human homolog of porcine genes from the Affymetrix array probes (67).
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agonist, MTII, reduced hepatic expression of the lipogenic
gene, stearoyl-CoA desaturase-1 (SCD1), and pretreatment
with SHU9119 reversed this effect (47). Mizuno et al. (54)
reported that transgenic POMC expression normalized expres-
sion of genes associated with hepatic carbohydrate metabolism
such as SCD-1, fatty acid transporter, protein tyrosine phos-
phatase 1B, and peroxisome proliferator-activated receptor-
coactivator in leptin-deficient obese mice. The authors sug-
gested that central POMC regulation of the expression of these
genes in the liver is most likely via the sympathetic nervous
system. Furthermore, Nogueiras et al. (56) reported that inhi-
bition of the MC3/4R promoted lipid uptake, triglyceride
synthesis, and fat accumulation, while stimulation of the
MC3/4R increased lipid mobilization. These effects were in-
dependent of food intake and changes in adiposity.
There are no reports on global transcriptional profiling of
adipose tissue after NDP-MSH treatment. In a related study,
the expression of several adipose tissue genes was determined
after central treatment of a melanocortin agonist in the Siberian
hamster (7). These authors were the first to demonstrate that
central administration of a melanocortin agonist, MTII, stim-
ulated adipose tissue lipolysis through the sympathetic nervous
system in the Siberian hamster (7). However, this study was of
limited scope with regard to adipose tissue gene expression
data.
A remarkable finding in our study is that NDP-MSH induced
upregulated expression of adipose tissue genes involved in the
structural morphogenesis and pattern specification of adipose
tissue, as indicated by three main GO Biological Processes of
development, regionalization, and determination of bilateral
symmetry being overrepresented among these genes. Similarly,
3 days of fasting in pigs upregulated expression of adipose
tissue genes involved in adipose tissue morphology and struc-
ture, since three main GO Biological Processes of cytoskeletal
organization, vasculature development, and branching struc-
ture development were overrepresented among adipose tissue
genes (49). However, NDP-MSH treatment apparently did not
influence other angiogenesis-related genes as did 3-day fasting
in pigs (49).
Unexpectedly, a group of genes upregulated by NDP-MSH
treatment directly or indirectly antagonize lipogenesis or adi-
pogenesis. For instance, ANGPTL4 was strongly upregulated
and inhibits LPL activity and angiogenic capacity (11, 26, 31).
Interleukin 15 also was upregulated and antagonizes lipogen-
esis by stimulating hormone-sensitive lipase (2). Furthermore,
IGFBP-3 was upregulated and directly or indirectly inhibits
adipogenesis (12, 35). Possibly, these genes are collectively
involved in dictating the sympathetic catabolic influence on
adipose tissue during fasting. Several other unexpected upregu-
lated genes linked to the adipocyte or adipogenesis included
pyruvate dehydrogenase kinase, isozyme 4 (PDK4), EGFR,
adiponectin, and ANG1. Additionally, UCP3 was also upregu-
lated by NDP-MSH treatment. PDK4 may play a role in
sympathetic induced metabolism, since it modulates the activ-
ity of adipose tissue glyceroneogenesis (10). Other targets of
sympathetic stimulation to adipose tissue included downregu-
lated lipid biosynthetic genes such as FASN, LPL, and leptin.
NDP-MSH induced downregulation of adipose tissue genes
involved in energy-generating related processes. Downregula-
tion of genes involved in direct energy-generating processes
such as oxidative phosphorylation and TCA was evident after
NDP-MSH treatment, and these genes were also prominently
downregulated in adipose tissue from fasted rats (46) and pigs
fasted for 3 days (49). Our data also demonstrate a metabolic
switch toward energy conservation similar to what was ob-
served in pigs fasted for 3 days (49). Downregulation of genes
involved in cofactor metabolism in adipose tissue was a major
cluster theme for NDP-MSH-treated and fasted pigs (49).
Additionally, genes involved in steroid metabolism and bio-
synthesis were downregulated in NDP-MSH-treated and fasted
pigs (49). An exception to these downregulated steroid metab-
olism and biosynthesis genes was a marked upregulation of
HSD3B1 in NDP-MSH-treated pigs. The HSD3B1 enzymatic
system plays a role in the biosynthesis of all classes of
hormonal steroids (72). The significance of upregulated
HSD3B1 in NDP-MSH-treated pigs remains to be determined.
Similarity of many gene cluster themes of downregulated
genes indicates that changes in gene expression was similar for
NDP-MSH-treated pigs and those fasted for 3 days (49). Our
studies indicate that much of the fasting response may be
attributable to stimulation of MC4R altering sympathetic flow
into adipose tissue.
Conclusions
The results of the present study demonstrate that the tran-
scriptional response to central administration of NDP-MSH in
part was similar to a metabolic response to energy deprivation
as previously reported in the pig (49). At the transcriptional
level, genes involved in lipid and carbohydrate metabolism in
liver and adipose tissue were differentially regulated following
NDP-MSH treatment depending on their anabolic/catabolic
function. In particular, a decrease in the expression of hepatic
and adipose tissue lipogenic genes occurred within 24 h post-
treatment. Furthermore, a unique group of genes that can
directly or indirectly antagonize lipogenesis or adipogenesis
were upregulated by NDP-MSH treatment in adipose tissue.
Most notably, ANGPTL4 was strongly upregulated and inhib-
its LPL activity and angiogenic capacity. Possibly, these genes
dictate the sympathetic catabolic influence on adipose tissue
during fasting. Although the results have put forward novel
ideas, further work is needed to substantiate the adaptive
response in gene expression to NDP-MSH.
ACKNOWLEDGMENTS
The authors thank Brent Jackson, Lara Lee-Rutherford, John Gamble, and
Carl Rogers.
Mention of a trade name, proprietary product, or specific equipment does
not constitute a guarantee or warranty by the U.S. Department of Agriculture,
the University of Georgia or Iowa State University and does not imply its
approval to the exclusion of other products that may be suitable.
GRANTS
This research was supported by United States Department of Agriculture,
National Research Initiative Grant USDA-NRI-2005-3560415618 and state
and hatch funds allocated to the Georgia Agriculture Experiment Station.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the authors.
REFERENCES
1. Adan RA, Tiesjema B, Hillebrand JJ, la Fleur SE, Kas MJ, de Krom
M. The MC4 receptor and control of appetite. Br J Pharmacol 149:
815–827, 2006.
266 MSH EFFECTS ON PATHWAYS IN HYPOTHALAMUS LIVER AND FAT
Physiol Genomics • VOL 41 • www.physiolgenomics.org
2. Ajuwon KM, Spurlock ME. Direct regulation of lipolysis by interleu-
kin-15 in primary pig adipocytes. Am J Physiol Regul Integr Comp Physiol
287: R608–R611, 2004.
3. Ang KL, Antoni FA. Reciprocal regulation of calcium dependent and
calcium independent cyclic AMP hydrolysis by protein phosphorylation. J
Neurochem 81: 422–433, 2002.
4. Barb CR, Chang WC, Leshin LS, Rampacek GB, Kraeling RR. Opioid
modulation of gonadotropin releasing hormone release from the hypotha-
lamic preoptic area in the pig. Domest Anim Endocrinol 11: 375–382,
1994.
5. Barb CR, Kraeling RR, Estienne MJ, Rampacek GB. Technique for
cannulation of the lateral ventricle of the brain in swine. Kopf Carrier 35:
1–5, 1993.
6. Barb CR, Robertson AS, Barrett JB, Kraeling RR, Houseknecht KL.
The role of melanocortin-3 and -4 receptor in regulating appetite, energy
homeostasis and neuroendocrine function in the pig. J Endocrinol 181:
39–52, 2004.
7. Brito MN, Brito NA, Baro DJ, Song CK, Bartness TJ. Differential
activation of the sympathetic innervation of adipose tissues by melano-
cortin receptor stimulation. Endocrinology 148: 5339–5347, 2007.
8. Butler AA. The melanocortin system and energy balance. Peptides 27:
281–290, 2006.
9. Butler AA, Cone RD. Knockout models resulting in the development of
obesity. Trends Genet 17: S50–S54, 2001.
10. Cadoudal T, Distel E, Durant S, Fouque F, Blouin JM, Collinet M,
Bortoli S, Forest C, Benelli C. Pyruvate dehydrogenase kinase 4: regu-
lation by thiazolidinediones and implication in glyceroneogenesis in adi-
pose tissue. Diabetes 57: 2272–2279, 2008.
11. Cazes A, Galaup A, Chomel C, Bignon M, Brechot N, Le Jan S, Weber
H, Corvol P, Muller L, Germain S, Monnot C. Extracellular matrix-
bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration,
and sprouting and alters actin cytoskeleton. Circ Res 99: 1207–1215,
2006.
12. Chan SS, Schedlich LJ, Twigg SM, Baxter RC. Inhibition of adipocyte
differentiation by insulin-like growth factor-binding protein-3. Am J
Physiol Endocrinol Metab 296: E654–E663, 2009.
13. Chu TM, Weir B, Wolfinger R. A systematic statistical linear modeling
approach to oligonucleotide array experiments. Math Biosci 176: 35–51,
2002.
14. Cone RD. The central melanocortin system and its role in energy ho-
meostasis. Ann Endocrinol (Paris) 60: 3–9, 1999.
15. Corssmit EP, Romijn JA, Sauerwein HP. Regulation of glucose pro-
duction with special attention to nonclassical regulatory mechanisms: a
review. Metabolism 50: 742–755, 2001.
16. Czaja K, Kraeling RR, Barb CR. Are hypothalamic neurons transsyn-
aptically connected to porcine adipose tissue? Biochem Biophys Res
Commun 311: 482–485, 2003.
17. Czaja K, Lakomy M, Sienkiewicz W, Kaleczyc J, Pidsudko Z, Barb
CR, Rampacek GB, Kraeling RR. Distribution of neurons containing
leptin receptors in the hypothalamus of the pig. Biochem Biophys Res
Commun 298: 333–337, 2002.
18. Dennis G, Jr, Sherman BT, Hosack DA, Yang H, Gao W, Lance HC,
Lempicki RA. DAVID: Database for Annotation, Visualization, and
Integrated Discovery. Genome Biol 4: P3, 2003.
19. Dyer CJ, Touchette KJ, Allee GL, Carroll JA, Matteri RL. Porcine
melanocortin agouti-related peptide: cloning, tissue distribution and quan-
tification of size-related differences in gene expression. J Anim Sci 78: 45,
2000.
20. Estienne MJ, Kesner JS, Barb CR, Kraeling RR, Rampacek GB,
Estienne CE. Gonadotropin and prolactin secretion following intraven-
tricular administration of morphine in gilts. Exp Biol Med (Maywood) 193:
92–97, 1990.
21. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell
Res 284: 14–30, 2003.
22. Fan ZC, Sartin JL, Tao YX. Molecular cloning and pharmacological
characterization of porcine melanocortin-3 receptor. J Endocrinol 196:
139–148, 2008.
23. Fan ZC, Sartin JL, Tao YX. Pharmacological analyses of two naturally
occurring porcine melanocortin-4 receptor mutations in domestic pigs.
Domest Anim Endocrinol 34: 383–390, 2008.
24. Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G,
Cheetham T, O’Rahilly S. Dominant and recessive inheritance of morbid
obesity associated with melanocortin 4 receptor deficiency. J Clin Invest
106: 271–279, 2000.
24a.Feng SQ, Chen XD, Xia T, Gan L, Qiu H, Dai MH, Zhou L, Peng Y,
Yang ZQ. Cloning, chromosome mapping and expression characteristics
of porcine ANGPTL3 and -4. Cytogenet Genome Res 114:44–49, 2006.
25. Finn PF, Dice JF. Proteolytic and lipolytic responses to starvation.
Nutrition 22: 830–844, 2006.
26. Galaup A, Cazes A, Le Jan S, Philippe J, Connault E, Le Coz E,
Mekid H, Mir LM, Opolon P, Corvol P, Monnot C, Germain S.
Angiopoietin-like 4 prevents metastasis through inhibition of vascular
permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci
USA 103: 18721–18726, 2006.
27. Giraudo SQ, Billington CJ, Levine AS. Feeding effects of hypothalamic
injection of melanocortin 4 receptor ligands. Brain Res 809: 302–306,
1998.
28. Gosmain Y, Dif N, Berbe V, Loizon E, Rieusset J, Vidal H, Lefai E.
Regulation of SREBP-1 expression and transcriptional action on HKII and
FAS genes during fasting and refeeding in rat tissues. J Lipid Res 46:
697–705, 2005.
29. Graham M, Shutter JR, Sarmiento U, Sarosi I, Stark KL. Overexpres-
sion of Agrt leads to obesity in transgenic mice. Nature Genet 17:
273–274, 1997.
30. Hart HA, Azain MJ, Hausman GJ, Reeves DE, Barb CR. Failure of
short term feed restriction to affect luteinizing hormone and leptin secre-
tion or subcutaneous adipose tissue expression of leptin in the prepuberal
gilt. Can J Anim Sci 87: 191–197. 2007.
31. Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in
angiogenesis and metabolism. Trends Cardiovasc Med 18: 6–14, 2008.
32. Hausman GJ, Barb CR, Dean RG. Patterns of gene expression in pig
adipose tissue: transforming growth factors, interferons, interleukins and
other cytokines. J Anim Sci 85: 2445–2456, 2007.
33. Hausman GJ, Barb CR, Dean RG. Patterns of gene expression in pig
adipose tissue: Insulin-like growth factor system proteins, neuropeptide Y
(NPY), NPY receptors, neurotrophic factors and other secreted factors.
Domest Anim Endocrinol 35: 24–34, 2008.
34. Hausman GJ, Richardson RL. Adrenergic innervation of fetal pig
adipose tissue. Histochem Ultrastruct Stud Acta Anat (Basel) 130: 291–
297, 1987.
35. Hausman GJ, Richardson RL, Simmen FA. Secretion of insulin-like
growth factor (IGF)-I and -II and IGF binding proteins (IGFBPs) in fetal
stromal-vascular (S-V) cell cultures obtained before and after the onset of
adipogenesis in vivo. Growth Dev Aging 66: 11–26, 2002.
36. Hochberg Z, Benjamini Y. Controlling the false discovery rate: a
practical and powerful approach to multiple testing. J Royal Stat Soc B:
289–300, 1995.
37. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed.
Summaries of Affymetrix GeneChip probe level data. Nucl Acids Res 31:
e15, 2003.
38. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M,
Katayama T, Kawashima S, Okuda S, Tokimatsu T, Yamanishi Y.
KEGG for linking genomes to life and the environment. Nucl Acids Res
36: D480–D484, 2008.
39. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes.
Nucl Acids Res 28: 27–30, 2000.
40. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M,
Kawashima S, Katayama T, Araki M, Hirakawa M. From genomics
to chemical genomics: new developments in KEGG. Nucl Acids Res 34:
D354-D357, 2006.
41. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli
W. Peroxisome proliferator-activated receptor alpha mediates the adaptive
response to fasting. J Clin Invest 103: 1489–1498, 1999.
42. Kim KS, Larsen N, Short T, Plastow G, Rothschild MF. A missense
variant of the porcine melanocortin-4 receptor (MC4R) gene is associated
with fatness, growth, and feed intake traits. Mamm Genome 11: 131–135,
2000.
43. Kim KS, Reecy JM, Hsu WH, Anderson LL, Rothschild MF. Func-
tional and phylogenetic analyses of a melanocortin-4 receptor mutation in
domestic pigs. Domest Anim Endocrinol 26: 75–86, 2004.
44. Kineman RD, Kraeling RR, Crim JW, Leshin LS, Barb CR, Ram-
pacek GB. Localization of proopiomelanocortin (POMC) immunoreactive
neurons in the forebrain of the pig. Biol Reprod 40: 1119–1126, 1989.
45. Kolev NG, Steitz JA. Symplekin and multiple other polyadenylation
factors participate in 3=-end maturation of histone mRNAs. Genes Dev 19:
2583–2592, 2005.
46. Li RY, Zhang QH, Liu Z, Qiao J, Zhao SX, Shao L, Xiao HS, Chen
JL, Chen MD, Song HD. Effect of short-term and long-term fasting on
267MSH EFFECTS ON PATHWAYS IN HYPOTHALAMUS LIVER AND FAT
Physiol Genomics • VOL 41 • www.physiolgenomics.org
transcriptional regulation of metabolic genes in rat tissues. Biochem
Biophys Res Commun 344: 562–570, 2006.
47. Lin J, Choi YH, Hartzell DL, Li C, Della-Fera MA, Baile CA. CNS
melanocortin and leptin effects on stearoyl-CoA desaturase-1 and resistin
expression. Biochem Biophys Res Commun 311: 324–328, 2003.
48. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS (R) System
for mixed models. SAS Inst Inc, Cary, NC 1996.
49. Lkhagvadorj S, QL, Cai W, Couture OP, Barb CR, Hausman GJ,
Nettleton D, Anderson LL, Dekkers JCM, Tuggle CK. Microarray gene
expression profiles of fasting induced changes in liver and adipose tissues
of pigs expressing the melanocortin-4 receptor D298N variant. Physiol
Genomics 38: 98–111, 2009.
50. Lok J, Sardi SP, Guo S, Besancon E, Ha DM, Rosell A, Kim WJ,
Corfas G, Lo EH. Neuregulin-1 signaling in brain endothelial cells. J
Cereb Blood Flow Metab 29: 39–43, 2009.
51. Lubrano-Berthelier C, Cavazos M, Le Stunff C, Haas K, Shapiro A,
Zhang S, Bougneres P, Vaisse C. The human MC4R promoter: charac-
terization and role in obesity. Diabetes 52: 2996–3000, 2003.
52. Marsh DJ, Hollopeter G, Huszar D, Laufer R, Yagaloff KA, Fisher
SL, Burn P, Palmiter RD. Response of melanocortin-4 receptor-deficient
mice to anorectic and orexigenic peptides. Nat Genet 21: 119–122, 1999.
53. Meehan TP, Tabeta K, Du X, Woodward LS, Firozi K, Beutler B,
Justice MJ. Point mutations in the melanocortin-4 receptor cause variable
obesity in mice. Mamm Genome 17: 1162–1171, 2006.
54. Mizuno TM, Kelley KA, Pasinetti GM, Roberts JL, Mobbs CV.
Transgenic neuronal expression of proopiomelanocortin attenuates hy-
perphagic response to fasting and reverses metabolic impairments in
leptin-deficient obese mice. Diabetes 52: 2675–2683, 2003.
55. Mounien L, Bizet P, Boutelet I, Vaudry H, Jegou S. Expression of
melanocortin MC3 and MC4 receptor mRNAs by neuropeptide Y neurons
in the rat arcuate nucleus. Neuroendocrinology 82: 164–170, 2005.
56. Nogueiras R, Wiedmer P, Perez-Tilve D, Veyrat-Durebex C, Keogh
JM, Sutton GM, Pfluger PT, Castaneda TR, Neschen S, Hofmann SM,
Howles PN, Morgan DA, Benoit SC, Szanto I, Schrott B, Schurmann
A, Joost HG, Hammond C, Hui DY, Woods SC, Rahmouni K, Butler
AA, Farooqi IS, O’Rahilly S, Rohner-Jeanrenaud F, Tschop MH. The
central melanocortin system directly controls peripheral lipid metabolism.
J Clin Invest 117: 3475–3488, 2007.
57. NRC. Nutrient Requirements of Pigs. Washington, DC: National Acad-
emy, 1998.
58. Obici S, Feng Z, Tan J, Liu L, Karkanias G, Rossetti L. Central
melanocortin receptors regulate insulin action. J Clin Invest 108: 1079–
1085, 2001.
59. Oosterom J, Garner KM, den Dekker WK, Nijenhuis WA, Gispen
WH, Burbach JP, Barsh GS, Adan RA. Common requirements for
melanocortin-4 receptor selectivity of structurally unrelated melanocortin
agonist and endogenous antagonist, Agouti protein. J Biol Chem 276:
931–936, 2001.
60. Pfaffl MW, Horgan G, Dempfle L. Relative expression software tool
(REST©) for group-wise comparison and statistical analysis of relative
expression results in real-time PCR. Nucl Acids Res 30: e36, 2002.
61. Poritsanos NJ, Wong D, Vrontakis ME, Mizuno TM. Regulation of
hepatic PPARgamma2 and lipogenic gene expression by melanocortin.
Biochem Biophys Res Commun 376: 384–388, 2008.
62. Ryu MH, Daily JW 3rd, Cha YS. Effect of starvation on hepatic
acyl-CoA synthetase, carnitine palmitoyltransferase-I, and acetyl-CoA
carboxylase mRNA levels in rats. Nutrition 21: 537–542, 2005.
63. SAS. SAS User’s Guide (release 8.0). Cary, NC: Statistical Analysis
Systems Institute, 1999.
64. Seeley RJ, Drazen DL, Clegg DJ. The critical role of the melanocortin
system in the control of energy balance. Annu Rev Nutr 24: 133–149,
2004.
65. Song CK, Jackson RM, Harris RB, Richard D, Bartness TJ. Melano-
cortin-4 receptor mRNA is expressed in sympathetic nervous system
outflow neurons to white adipose tissue. Am J Physiol Regul Integr Comp
Physiol 289: R1467–R1476, 2005.
66. Soupene E, Kuypers FA. Mammalian long-chain acyl-CoA synthetases.
Exp Biol Med (Maywood) 233: 507–521, 2008.
67. Tasi S, Cassady JP, Freking BA, Nonneman DJ, Rohrer GA, Piedra-
hita JA. Annotation of the Affymetrix porcine genome microarray. Anim
Genet 37: 423–424, 2006.
68. Tatro JB. Receptor biology of the melanocortins, a family of neuroim-
munomodulatory peptides. Neuroimmunomodulation 3: 259–284, 1996.
69. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel
P. Melanocortin-4 receptor mutations are a frequent and heterogeneous
cause of morbid obesity. J Clin Invest 106: 253–262, 2000.
70. Vergoni AV, Schioth HB, Bertolini A. Melanocortins and feeding
behavior. Biomed Pharmacother 54: 129–134, 2000.
71. Voss-andreae A, Murphy JG, Ellacott KL, Stuart RC, Nillni EA, Cone
RD, Fan W. Role of the central melanocortin circuitry in adaptive
thermogenesis of brown adipose tissue. Endocrinology 148: 1550–1560,
2007.
72. Wang L, Salavaggione E, Pelleymounter L, Eckloff B, Wieben E,
Weinshilboun R. Human 3-hydroxysteroid dehydrogenase types 1 and
2: Gene sequence variation and functional genomics. J Steroid Biochem
Mol Biol 107: 88–99, 2007.
73. Wirth MM, Giraudo SQ. Agouti-related protein in the hypothalamic
paraventricular nucleus: effect on feeding. Peptides 21: 1369–1375, 2000.
74. Wolfinger RD, Gibson G, Wolfinger ED, Bennett L, Hamadeh H,
Bushel P, Afshari C, Paules RS. Assessing gene significance from cDNA
microarray expression data via mixed models. J Comput Biol 8: 625–637,
2001.
75. Yoshida K, Shimizugawa T, Ono M, Furukawa H. Angiopoietin-like
protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor
of lipoprotein lipase. J Lipid Res 43: 1770–1772, 2002.
268 MSH EFFECTS ON PATHWAYS IN HYPOTHALAMUS LIVER AND FAT
Physiol Genomics • VOL 41 • www.physiolgenomics.org
